Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.

About ABRAXANE (R)

The U.S. Food and Drug Administration approved ABRAXANE (R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:5/16/2008)...nd customer thought leaders -, SAN FRANCISCO, May...ader and trusted resource for clinical trial manag...prestigious academic medical centers, research,ins... group meeting in San,Francisco. The Velos eResear...boratively manage thousands of clinical trials., ...
(Date:5/16/2008)...r PEGylation of a Small Molecule with ...OS, Calif., May 16 /- Nekta...results today from a Phase 1,study of NKTR- 102, P...ti-tumor activity in patients with refractory soli...s small molecule PEGylation technology,produced an...
(Date:5/16/2008)... Significant Reductions in Selected ...ublished in 2008 Proceedings of the American Socie... SAN DIEGO, May 16 /- ADVE... today that, in a registrational bioequivalence,cl... significant reduction,in general disorders and ad...
(Date:5/15/2008)...FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN ) to...clinical,trial of its novel androgen receptor anta...entation at the 44th American Society of Clinical ...sion title: New Targeted Strategies for Patients w..., June 2 at 11:30 a.m. Central Time Abstract titl...
Breaking Medicine Technology:Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 1PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 2PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade 28TM 29 3260 3 2437 million financing for company based on macular degeneration research 3256 1 2437 million financing for company based on macular degeneration research 3256 2Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 1Lunch Lady Challenges Schools Families to Make Kids Nutrition a Priority 3251 2Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 1Angel Flight West Recognizes Southern California Pilots at 24th Anniversary 3246 2
(Date:5/16/2008)...EWPORT BEACH, Calif., May 16 /PRNewswire-FirstCall...P ) announced today the promotion of David,M. Boit... Officer. "Dave,has made a tremendous contribution...y our strong investment growth and diversification... over $1 billion in accretive,investments for NHP,...
(Date:5/16/2008)...AN DIEGO, May 16 /PRNewswire-FirstCall/ -- CryoCor...cused on the treatment of cardiac,arrhythmias, ann...ers of,CryoCor common stock filed a complaint in t...ty of San Diego, naming as defendants each member ...Boston Scientific Corporation.,The complaint is st...
(Date:5/16/2008)...ment guidelines quickly disseminated to community ...16 (HealthDay News) -- Partnerships between major ...e a quick and effective way to spread cancer treat... Center in Philadelphia. , Most new cancer trea...ost cancer care is provided at community hospitals...
(Date:5/16/2008)...ismatch in some early stage cases makes therapy of...RIDAY, May 16 (HealthDay News) -- Colon cancer pat...need to receive chemotherapy. In fact, not only do..., it may actually harm them, a new study found. ,...ncer], then you should not be treated with chemoth...
Breaking Medicine News(10 mins):Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2
...eening system combining digital photography with I...method to screen for a common childhood oral disea...ty toddlers. Early childhood dental caries (ECC... tooth decay, results from prolonged exposure to s...
...study published in the journal, Cell Metabolism, r...ion in the zebrafish that are remarkably similar t...es disease that could aid in finding new therapies...ead to the aquarium fish becoming an important ani...
... mothers may someday get a personalized menu of fo...netic makeup as a result of new research at Washin... Researchers used transparent fish embryos to dev...genes and diet interact to cause birth defects. "...
...can children with asthma make more clinic visits t... severity.// Asthma has been on the rise for the ... especially high prevalence. A study in the August...hat Puerto Rican children with asthma make more cl...
Other Medicine News:Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 2Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 4Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3Health News:Children of Different Race Show Different Patterns of Asthma Care 2
Self retaining brain retractor.
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required.
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm).
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm).
Medicine Products: